Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Daratumumab + Dexamethasone in t(11;14) AL Amyloidosis
NCT05486481Phase 2Withdrawn
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of venetoclax in systemic light chain amyloidosis. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Planned start Jan 2024; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT05486481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486481.